SmithKline Beecham Twinrix
Immunogencity rates following administration of the combination hepatitis A/hepatitis B vaccine Twinrix were statistically equivalent to protection from separately administered hep A (Havrix) and hep B (Engerix B) vaccines, Phase III data presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco indicate. The open-label study conducted at two centers evaluated 773 patients randomized to receive either three doses of Twinrix at 0, 1 and 6 months, or Havrix at 0 and 6 months and Engerix B at 0, 1 and 6 months. The combination vaccine "has the advantage of reducing the number of injections needed (3 vs. 5), increasing the convenience of administration and...compliance to vaccination schedules," SmithKline concluded. Twinrix, already approved in the U.K., is currently under review at FDA
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth